Baytan Secur

How often in a day do you take medicine? How many times?
advertisement

Baytan Secur uses

Baytan Secur consists of Fuberidazole, Imidacloprid, Triadimenol.

Imidacloprid:



Once-a-month topical solution for the prevention of heartworm disease, the treatment of circulating microfilariae, kills adult fleas, is indicated for the treatment of flea infestations, the treatment and control of sarcoptic mange, as well as the treatment and control of intestinal parasite infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.

WARNING

  • DO NOT ADMINISTER THIS PRODUCT ORALLY
  • For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.
  • Children should not come in contact with application sites for two (2) hours after application.


CAUTION:

Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

Advantage Multi® for Dogs (10 % Baytan Secur (Imidacloprid) + 2.5 % moxidectin) is a colorless to yellow ready-to-use solution packaged in single dose applicator tubes for topical treatment of dogs. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (10 mg/kg) Baytan Secur (Imidacloprid) and 1.1 mg/lb (2.5 mg/kg) moxidectin based on body weight.

Baytan Secur (Imidacloprid) is a chloronicotinyl nitroguanidine insecticide. The chemical name for Baytan Secur (Imidacloprid) is 1-[(6-Chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete Streptomycetes cyaneogriseus noncyanogenus. The chemical name for moxidectin is [6R, 23E, 25S(E)]-5-O- Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino) milbemycin B.

advertisement

INDICATIONS:

Baytan Secur (Imidacloprid) is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Baytan Secur (Imidacloprid) kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). Baytan Secur (Imidacloprid) is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. Baytan Secur (Imidacloprid) is also indicated for the treatment and control of the following intestinal parasites:


Intestinal Parasite


Intestinal Stage


Adult


Immature

Adult


Fourth Stage

Larvae


Hookworm Species


Ancylostoma caninum


X


X


X


Uncinaria stenocephala


X


X


X


Roundworm Species


Toxocara canis


X


X


Toxascaris leonina


X


Whipworm


Trichuris vulpis


X

advertisement

CONTRAINDICATIONS:

Do not administer this product orally.

Do not use this product (containing 2.5% moxidectin) on cats.

WARNINGS

For the first 30 minutes after application:

Ensure that dogs cannot lick the product from application sites on themselves or other treated dogs, and

Separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion.

Ingestion of this product by dogs may cause serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.

In avermectin sensitive dogs,a the signs may be more severe and may include coma and death.b

a Some dogs are more sensitive to avermectins due to a mutation in the MDR1 gene. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses.

b Although there is no specific antagonist for avermectin toxicity, even severely affected dogs have completely recovered from avermectin toxicity with intensive veterinary supportive care.

HUMAN WARNINGS:

Not for human use. Keep out of the reach of children.

Children should not come in contact with application sites for two (2) hours after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin.

Wash hands thoroughly with soap and warm water after handling.

If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, Baytan Secur (Imidacloprid) or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety information. For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call Bayer Veterinary Services at 1-800-422-9874. For consumer questions call 1-800-255-6826.

advertisement

PRECAUTIONS:

Do not dispense dose applicator tubes without complete safety and administration information.

Use with caution in sick, debilitated, or underweight animals. The safety of Baytan Secur (Imidacloprid) has not been established in breeding, pregnant, or lactating dogs. The safe use of Baytan Secur (Imidacloprid) has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight.

Prior to administration of Baytan Secur (Imidacloprid), dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of Baytan Secur (Imidacloprid) has not been evaluated when administered on the same day as an adulticide. Baytan Secur (Imidacloprid) is not effective against adult D. immitis. Although the number of circulating microfilariae is substantially reduced in most dogs following treatment with Baytan Secur (Imidacloprid), the microfilaria count in some heartworm-positive dogs may increase or remain unchanged following treatment with Baytan Secur (Imidacloprid) alone or in a dosing regimen with melarsomine dihydrochloride.


Baytan Secur (Imidacloprid) has not been evaluated in heartworm-positive dogs with Class 4 heartworm disease.

ADVERSE REACTIONS:

Heartworm-Negative Dogs

Field Studies: Following treatment with Baytan Secur (Imidacloprid) or an active control, dog owners reported the following post-treatment reactions:


OBSERVATION


Advantage Multi n=128


Active Control n=68


Pruritus


19 dogs (14.8%)


7 dogs (10.3%)


Residue


9 dogs (7.0%)


5 dogs (7.4%)


Medicinal Odor


5 dogs (3.9%)


None observed


Lethargy


1 dog (0.8%)


1 dog (1.5%)


Inappetence


1 dog (0.8%)


1 dog (1.5%)


Hyperactivity


1 dog (0.8%)


None observed


During a field study using 61 dogs with pre-existing flea allergy dermatitis, one (1.6 %) dog experienced localized pruritus immediately after Baytan Secur (Imidacloprid) application, and one investigator noted hyperkeratosis at the application site of one dog (1.6 %).

In a field safety and effectiveness study, Baytan Secur (Imidacloprid) was administered to 92 client-owned dogs with sarcoptic mange. The dogs ranged in age from 2 months to 12.5 years and ranged in weight from 3 to 231.5 pounds. Adverse reactions in dogs treated with Baytan Secur (Imidacloprid) included hematochezia, diarrhea, vomiting, lethargy, inappetence, and pyoderma.

Laboratory Effectiveness Studies: One dog in a laboratory effectiveness study experienced weakness, depression, and unsteadiness between 6 and 9 days after application with Baytan Secur (Imidacloprid). The signs resolved without intervention by day 10 post-application. The signs in this dog may have been related to peak serum levels of moxidectin, which vary between dogs, and occur between 1 and 21 days after application of Baytan Secur (Imidacloprid).

The following clinical observations also occurred in laboratory effectiveness studies following application with Baytan Secur (Imidacloprid) and may be directly attributed to the drug or may be secondary to the intestinal parasite burden or other underlying conditions in the dogs: diarrhea, bloody stools, vomiting, anorexia, lethargy, coughing, ocular discharge and nasal discharge. Observations at the application sites included damp, stiff or greasy hair, the appearance of a white deposit on the hair, and mild erythema, which resolved without treatment within 2 to 48 hours.

Heartworm-Positive Dogs

Field Study: A 56-day field safety study was conducted in 214 D. immitis heartworm and microfilaria positive dogs with Class 1, 2 or 3 heartworm disease. All dogs received Baytan Secur (Imidacloprid) on Study Days 0 and 28; 108 dogs also received melarsomine dihydrochloride on Study Days – 14, 14, and 15. All dogs were hospitalized for a minimum of 12 hours following each treatment. Effectiveness against circulating D. immitis microfilariae was > 90 % at five of six sites; however, one site had an effectiveness of 73.3 %. The microfilaria count in some heartworm-positive dogs increased or remained unchanged following treatment with Baytan Secur (Imidacloprid) alone or in a dosing regimen with melarsomine dihydrochloride.

Following treatment with Baytan Secur (Imidacloprid) alone or in a dosing regimen with melarsomine dihydrochloride, the following adverse reactions were observed:


Adverse Reaction


Dogs Treated with

Advantage Multi for

Dogs Only

n=106


Dogs Treated with

Baytan Secur (Imidacloprid)

+ Melarsomine

n=108


Cough


24 (22.6%)


25 (23.1%)


Lethargy


14 (13.2%)


42 (38.9%)


Vomiting


11 (10.4%)


18 (16.7%)


Diarrhea, including

hemorrhagic


10 (9.4%)


22 (20.4%)


Inappetence


7 (6.6%)


19 (17.6%)


Dyspnea


6 (5.7%)


10 (9.3%)


Tachypnea


1 (<1%)


7 (6.5%)


Pulmonary

Hemorrhage


0


1 (<1%)


Death


0


3 (2.8%)


Three dogs treated with Baytan Secur (Imidacloprid) in a dosing regimen with melarsomine dihydrochloride died of pulmonary embolism from dead and dying heartworms. One dog, treated with Baytan Secur (Imidacloprid) and melarsomine dihydrochloride, experienced pulmonary hemorrhage and responded to supportive medical treatment. Following the first treatment with Baytan Secur (Imidacloprid) alone, two dogs experienced adverse reactions (coughing, vomiting, and dyspnea) that required hospitalization. In both groups, there were more adverse reactions to Baytan Secur (Imidacloprid) following the first treatment than the second treatment.

To report a suspected adverse reaction, call 1-800-422-9874.

Post-Approval Experience

The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in dogs are listed in decreasing order of reporting frequency: depression/lethargy, vomiting, pruritus, diarrhea, anorexia, hyperactivity, ataxia, trembling, hypersalivation, application site reactions (alopecia, pruritus, lesions, and erythema), seizures, and anaphylaxis/anaphylactic reactions (hives, urticaria, facial swelling, edema of the head).

Serious reactions, including neurologic signs and death have been reported when cats have been exposed (orally and topically) to this product.

In humans, nausea, numbness or tingling of the mouth/lips and throat, ocular and dermal irritation, pruritus, headache, vomiting, diarrhea, depression and dyspnea have been reported following exposure to this product.

To report suspected adverse events and/or obtain a copy of the SDS or for technical assistance, call Bayer Animal Heath at 1-800-422-9874.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.

advertisement

DOSAGE AND ADMINISTRATION:

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) Baytan Secur (Imidacloprid) and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Do not apply to irritated skin.

1. Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the Advantage Multi for Dogs tube that correctly corresponds with the body weight of the dog.


Dog (lbs.)


Baytan Secur (Imidacloprid)


Volume (mL)


Baytan Secur (Imidacloprid)

(mg)


Moxidectin

(mg)


3–9


Advantage Multi 9


0.4


40


10


9.1–20


Advantage Multi 20


1.0


100


25


20.1–55


Advantage Multi 55


2.5


250


62.5


55.1–88


Advantage Multi 88


4.0


400


100


88.1–110Dogs over 110 lbs. should be treated with the appropriate combination of Baytan Secur (Imidacloprid) tubes.


Advantage Multi 110


5.0


500


125


2. While holding the tube in an upright position, remove the cap from the tube.

3. Turn the cap over and push the other end of cap onto the tip of the tube.

4. Twist the cap to break the seal and then remove cap from the tube.

5. The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. For dogs weighing 20 lbs. or less, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog.

Do not let this product get in your dog’s mouth or eyes. Do not allow the dog to lick any of the application sites for 30 minutes. In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites.


Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product.

Shampooing 90 minutes after treatment does not reduce the effectiveness of Baytan Secur (Imidacloprid) in the prevention of heartworm disease.

Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of Baytan Secur (Imidacloprid) in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

Heartworm Prevention: For prevention of heartworm disease, Baytan Secur (Imidacloprid) should be administered at one-month intervals. Baytan Secur (Imidacloprid) may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer Baytan Secur (Imidacloprid) immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with Baytan Secur (Imidacloprid) should be given within one month of the last dose of the former medication.

Treatment of Circulating Microfilaria: For the treatment of circulating D. immitis microfilaria in heartworm-positive dogs, Baytan Secur (Imidacloprid) should be administered at one-month intervals. Treatment with an approved adulticide therapy is recommended because Baytan Secur (Imidacloprid) is not effective for the treatment of adult D. immitis.


Flea Treatment: For the treatment of flea infestations, Advantage Multi for Dogs should be administered at one-month intervals. If the dog is already infested with fleas when the first dose of Baytan Secur (Imidacloprid) is administered, adult fleas on the dog will be killed. However, reinfestation from the emergence of preexisting pupae in the environment may continue to occur for six weeks or longer after treatment is initiated. Dogs treated with Baytan Secur (Imidacloprid), including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the dog.

Treatment and Control of Intestinal Nematode Infections:

For the treatment and control of intestinal hookworm infections caused by Ancylostoma caninum and Uncinaria stenocephala (adults, immature adults and fourth stage larvae) and roundworm infections caused by Toxocara canis (adults and fourth stage larvae), and Toxascaris leonina (adults), and whipworm infections caused by Trichuris vulpis (adults), Baytan Secur (Imidacloprid) should be administered once as a single topical dose.

Treatment and Control of Sarcoptic Mange: For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis, Baytan Secur (Imidacloprid) should be administered as a single topical dose. A second monthly dose may be administered if necessary.

Depiction of opening of the Baytan Secur (Imidacloprid) tube Depiction of application of Baytan Secur (Imidacloprid) on the dog's skin

ANIMAL SAFETY:

Heartworm-Negative Dogs

Field Study: In a controlled, double-masked, field safety study, Baytan Secur was administered to 128 dogs of various breeds, 3 months to 15 years of age, weighing 4 to 157 pounds. Baytan Secur (Imidacloprid) was used safely in dogs concomitantly receiving ACE inhibitors, anticonvulsants, antihistamines, antimicrobials, chondroprotectants, corticosteroids, immunotherapeutics, MAO inhibitors, NSAIDs, ophthalmic medications, sympathomimetics, synthetic estrogens, thyroid hormones, and urinary acidifiers. Owners reported the following signs in their dogs after application of Baytan Secur (Imidacloprid): pruritus, flaky/greasy residue at the treatment site, medicinal odor, lethargy, inappetence, and hyperactivity.


Safety Study in Puppies: Baytan Secur (Imidacloprid) was applied topically at 1, 3 and 5X the recommended dose to 7-week-old Beagle puppies once every 2 weeks for 6 treatments on days 0, 14, 28, 42, 56, and 70. Loose stools and diarrhea were observed in all groups, including the controls, throughout the study. Vomiting was seen in one puppy from the 1X treatment group (day 57), in two puppies from the 3X treatment group (days 1 and 79), and in one puppy from the 5X treatment group (day 1). Two puppies each in the 1X, 3X, and 5X groups had decreased appetites within 24 hours post-dosing. One puppy in the 1X treatment group had pruritus for one hour following the fifth treatment. A puppy from the 5X treatment group displayed rapid, difficult breathing from 4 to 8 hours following the second treatment.

Dermal Dose Tolerance Study: Baytan Secur (Imidacloprid) was administered topically to 8-month-old Beagle dogs at 10X the recommended dose once. One dog showed signs of treatment site irritation after application. Two dogs vomited, one at 6 hours and one at 6 days post-treatment. Increased RBC, hemoglobin, activated partial thromboplastin, and direct bilirubin were observed in the treated group. Dogs in the treated group did not gain as much weight as the control group.

Oral Safety Study in Beagles: Baytan Secur (Imidacloprid) was administered once orally at the recommended topical dose to 12 dogs. Six dogs vomited within 1 hour of receiving the test article, 2 of these dogs vomited again at 2 hours, and 1 dog vomited again up to 18 hours post-dosing. One dog exhibited shaking (nervousness) 1 hour post-dosing. Another dog exhibited abnormal neurological signs (circling, ataxia, generalized muscle tremors, and dilated pupils with a slow pupillary light response) starting at 4 hours post-dosing through 18 hours postdosing. Without treatment, this dog was neurologically normal at 24 hours and had a normal appetite by 48 hours post-dosing.


Dermal Safety Study in Ivermectin-Sensitive Collies:

Baytan Secur (Imidacloprid) was administered topically at 3 and 5X the recommended dose every 28 days for 3 treatments to Collies which had been prescreened for avermectin sensitivity. No clinical abnormalities were observed.

Oral Safety Study in Ivermectin-Sensitive Collies:

Baytan Secur (Imidacloprid) was administered orally to 5 pre-screened ivermectin-sensitive Collies. The Collies were asymptomatic after ingesting 10 % of the minimum labeled dose. At 40 % of the minimum recommended topical dose, 4 of the dogs experienced neurological signs indicative of avermectin toxicity including depression, ataxia, mydriasis, salivation, muscle fasciculation, and coma, and were euthanized.


Heartworm-Positive Dogs

Laboratory Safety Study in Heartworm-Positive Dogs: Baytan Secur (Imidacloprid) was administered topically at 1 and 5X the recommended dose every 14 days for 3 treatments to dogs with adult heartworm infections and circulating microfilaria. At 5X, one dog was observed vomiting three hours after the second treatment. Hypersensitivity reactions were not seen in the 5X treatment group. Microfilaria counts decreased with treatment.

STORAGE INFORMATION:

Store at temperatures between 4 °C (39 °F) and 25 °C (77 °F), avoiding excess heat or cold.

HOW SUPPLIED:

Applications Per Package:

6 x 0.4 mL tubes

6 x 1.0 mL tubes

6 x 2.5 mL tubes

6 x 4.0 mL tubes

6 x 5.0 mL tubes

Advantage Multi is protected by one or more of the following U.S. patents:

6,232,328, and 6,001,858.

84780812 v-06/2015

NADA # 141-251, Approved by FDA

Made in Germany

© 2015 Bayer HealthCare LLC

Bayer, the Bayer Cross and Advantage Multi are registered trademarks of Bayer

Bayer HealthCare LLC

Animal Health Division

P.O. Box 390

Shawnee Mission

Kansas 66201 U.S.A.

Bayer logo

advantage multi®

for dogs

(imidacloprid + moxidectin)

Topical Solution

CAUTION: Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian

Once-A-Month Topical Solution

  • Prevention of heartworm disease
  • Treatment of Dirofilaria immitis circulating microfilariae
  • Kills adult fleas and is indicated for the treatment of flea infestations
  • Treatment and control of hookworms, roundworms, and whipworms
  • Treatment and control of sarcoptic mange
  • For dogs and puppies 7 weeks of age and older and 3 to 9 lbs.

WARNING

  • DO NOT ADMINISTER THIS PRODUCT ORALLY
  • For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.
  • Children should not come in contact with application sites for two (2) hours after application.


Each tube contains 40 mg of Baytan Secur (Imidacloprid) and 10 mg of moxidectin.

Keep this and all drugs out of the reach of children.

Do not use this product on cats.

NADA # 141-251, Approved by FDA

SIX 0.4 mL Tubes

advantage multi®

for dogs

(imidacloprid + moxidectin)

Topical Solution

CAUTION: Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian

Once-A-Month Topical Solution

  • Prevention of heartworm disease
  • Treatment of Dirofilaria immitis circulating microfilariae
  • Kills adult fleas and is indicated for the treatment of flea infestations
  • Treatment and control of hookworms, roundworms, and whipworms
  • Treatment and control of sarcoptic mange
  • For dogs and puppies 7 weeks of age and older and 9.1 to 20 lbs.

WARNING

  • DO NOT ADMINISTER THIS PRODUCT ORALLY
  • For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.
  • Children should not come in contact with application sites for two (2) hours after application.


Each tube contains 100 mg of Baytan Secur (Imidacloprid) and 25 mg of moxidectin.

Keep this and all drugs out of the reach of children.

Do not use this product on cats.

NADA # 141-251, Approved by FDA

SIX 1.0 mL Tubes

advantage multi®

for dogs

(imidacloprid + moxidectin)

Topical Solution

CAUTION: Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian

Once-A-Month Topical Solution

  • Prevention of heartworm disease
  • Treatment of Dirofilaria immitis circulating microfilariae
  • Kills adult fleas and is indicated for the treatment of flea infestations
  • Treatment and control of hookworms, roundworms, and whipworms
  • Treatment and control of sarcoptic mange
  • For dogs and puppies 7 weeks of age and older and 20.1 to 55 lbs.

WARNING

  • DO NOT ADMINISTER THIS PRODUCT ORALLY
  • For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.
  • Children should not come in contact with application sites for two (2) hours after application.


Each tube contains 250 mg of Baytan Secur (Imidacloprid) and 62.5 mg of moxidectin.

Keep this and all drugs out of the reach of children.

Do not use this product on cats.

NADA # 141-251, Approved by FDA

SIX 2.5 mL Tubes

advantage multi®

for dogs

(imidacloprid + moxidectin)

Topical Solution

CAUTION: Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian

Once-A-Month Topical Solution

  • Prevention of heartworm disease
  • Treatment of Dirofilaria immitis circulating microfilariae
  • Kills adult fleas and is indicated for the treatment of flea infestations
  • Treatment and control of hookworms, roundworms, and whipworms
  • Treatment and control of sarcoptic mange
  • For dogs and puppies 7 weeks of age and older and 55.1 to 88 lbs.

WARNING

  • DO NOT ADMINISTER THIS PRODUCT ORALLY
  • For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.
  • Children should not come in contact with application sites for two (2) hours after application.


Each tube contains 400 mg of Baytan Secur (Imidacloprid) and 100 mg of moxidectin.

Keep this and all drugs out of the reach of children.

Do not use this product on cats.

NADA # 141-251, Approved by FDA

SIX 4.0 mL Tubes

advantage multi®

for dogs

(imidacloprid + moxidectin)

Topical Solution

CAUTION: Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian

Once-A-Month Topical Solution

  • Prevention of heartworm disease
  • Treatment of Dirofilaria immitis circulating microfilariae
  • Kills adult fleas and is indicated for the treatment of flea infestations
  • Treatment and control of hookworms, roundworms, and whipworms
  • Treatment and control of sarcoptic mange
  • For dogs and puppies 7 weeks of age and older and 88.1 to 110 lbs.

WARNING

  • DO NOT ADMINISTER THIS PRODUCT ORALLY
  • For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.
  • Children should not come in contact with application sites for two (2) hours after application.


Each tube contains 500 mg of Baytan Secur (Imidacloprid) and 125 mg of moxidectin.

Keep this and all drugs out of the reach of children.

Do not use this product on cats.

NADA # 141-251, Approved by FDA

SIX 5.0 mL Tubes

Baytan Secur pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Baytan Secur available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.


Baytan Secur destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Baytan Secur Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Baytan Secur pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

References

  1. Dailymed."ADVANTUS SOFT CHEW (IMIDACLOPRID) TABLET, CHEWABLE [BAYER HEALTHCARE, LLC ANIMAL HEALTH DIVISION]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "Imidacloprid". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  3. "Imidacloprid". http://www.drugbank.ca/drugs/DB1142... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Baytan Secur?

Depending on the reaction of the Baytan Secur after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Baytan Secur not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Baytan Secur addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Baytan Secur, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Baytan Secur consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 28 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology

© 2002 - 2024 "sdrugs.com". All Rights Reserved